Alligator Bioscience AB (publ) (ATORX.ST)
SEK 6.3
(-3.37%)
SEK 6.3
(-3.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -50.02 Million SEK | 31.29% |
| 2022 | -72.8 Million SEK | 72.88% |
| 2021 | -268.41 Million SEK | -194.09% |
| 2020 | -91.26 Million SEK | 49.24% |
| 2019 | -179.81 Million SEK | 50.45% |
| 2018 | -362.87 Million SEK | 23.27% |
| 2017 | -472.91 Million SEK | 28.25% |
| 2016 | -659.13 Million SEK | -80.29% |
| 2015 | -365.6 Million SEK | -876.82% |
| 2014 | -37.42 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -26.07 Million SEK | 47.86% |
| 2024 Q3 | -39.18 Million SEK | 42.42% |
| 2024 Q2 | -65.71 Million SEK | -151.98% |
| 2023 FY | -50.02 Million SEK | 31.29% |
| 2023 Q2 | -139.65 Million SEK | -549.12% |
| 2023 Q1 | -21.51 Million SEK | 70.45% |
| 2023 Q3 | -55.46 Million SEK | 60.28% |
| 2023 Q4 | -50.02 Million SEK | 9.82% |
| 2022 Q2 | -172.22 Million SEK | 18.78% |
| 2022 FY | -72.8 Million SEK | 72.88% |
| 2022 Q4 | -72.8 Million SEK | 43.33% |
| 2022 Q3 | -128.46 Million SEK | 25.41% |
| 2022 Q1 | -212.04 Million SEK | 21.0% |
| 2021 Q4 | -268.41 Million SEK | -295.91% |
| 2021 FY | -268.41 Million SEK | -194.09% |
| 2021 Q3 | -67.79 Million SEK | 33.06% |
| 2021 Q2 | -101.27 Million SEK | 23.22% |
| 2021 Q1 | -131.91 Million SEK | -44.53% |
| 2020 Q4 | -91.26 Million SEK | 26.54% |
| 2020 Q2 | -155.58 Million SEK | 17.07% |
| 2020 FY | -91.26 Million SEK | 49.24% |
| 2020 Q1 | -187.6 Million SEK | -4.33% |
| 2020 Q3 | -124.24 Million SEK | 20.14% |
| 2019 FY | -179.81 Million SEK | 50.45% |
| 2019 Q4 | -179.81 Million SEK | 18.67% |
| 2019 Q3 | -221.08 Million SEK | 16.78% |
| 2019 Q2 | -265.65 Million SEK | 13.99% |
| 2019 Q1 | -308.85 Million SEK | 14.89% |
| 2018 Q4 | -362.87 Million SEK | 10.33% |
| 2018 Q3 | -404.68 Million SEK | 8.97% |
| 2018 Q2 | -444.57 Million SEK | 6.34% |
| 2018 Q1 | -474.68 Million SEK | -0.37% |
| 2018 FY | -362.87 Million SEK | 23.27% |
| 2017 Q1 | -639.73 Million SEK | 2.94% |
| 2017 Q3 | -513.22 Million SEK | 5.05% |
| 2017 FY | -472.91 Million SEK | 28.25% |
| 2017 Q2 | -540.51 Million SEK | 15.51% |
| 2017 Q4 | -472.91 Million SEK | 7.85% |
| 2016 FY | -659.13 Million SEK | -80.29% |
| 2016 Q4 | -659.13 Million SEK | -90.25% |
| 2016 Q3 | -346.45 Million SEK | 0.0% |
| 2016 Q1 | 365.6 Million SEK | 200.0% |
| 2015 Q4 | -365.6 Million SEK | 0.0% |
| 2015 FY | -365.6 Million SEK | -876.82% |
| 2014 FY | -37.42 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1026.315% |
| AcouSort AB (publ) | -23.98 Million SEK | -108.542% |
| Active Biotech AB (publ) | -33.2 Million SEK | -50.666% |
| Alzinova AB (publ) | -21.22 Million SEK | -135.659% |
| Amniotics AB (publ) | -5.63 Million SEK | -788.157% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2214.715% |
| BioArctic AB (publ) | -606.58 Million SEK | 91.754% |
| Camurus AB (publ) | -1.16 Billion SEK | 95.708% |
| Cantargia AB (publ) | -139.74 Million SEK | 64.206% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -5319.393% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -70.238% |
| Genovis AB (publ.) | -43.94 Million SEK | -13.837% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 40.267% |
| Mendus AB (publ) | -96.29 Million SEK | 48.054% |
| Kancera AB (publ) | -45.69 Million SEK | -9.474% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 39.149% |
| LIDDS AB (publ) | -13.51 Million SEK | -270.197% |
| Lipum AB (publ) | -8.46 Million SEK | -490.916% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -56.673% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 193.984% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -162.44% |
| NextCell Pharma AB | -46.79 Million SEK | -6.904% |
| OncoZenge AB (publ) | -12.62 Million SEK | -296.143% |
| Saniona AB (publ) | 40.44 Million SEK | 223.67% |
| Simris Alg AB (publ) | 85.07 Million SEK | 158.796% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 85.007% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 130.119% |
| Xintela AB (publ) | -7.8 Million SEK | -540.556% |
| Ziccum AB (publ) | -2.13 Million SEK | -2240.711% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 63.792% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 61.372% |
| CombiGene AB (publ) | -101.44 Million SEK | 50.689% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 39.063% |
| Intervacc AB (publ) | -88.16 Million SEK | 43.261% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -0.174% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 343.886% |
| Corline Biomedical AB | -17.01 Million SEK | -194.034% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 40.268% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -27.015% |
| Aptahem AB (publ) | 2.9 Million SEK | 1819.737% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 84.799% |
| Fluicell AB (publ) | -2.76 Million SEK | -1710.387% |
| Biovica International AB (publ) | -58.73 Million SEK | 14.839% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -10.624% |
| Abliva AB (publ) | -57.24 Million SEK | 12.612% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 74.309% |
| 2cureX AB (publ) | -13.4 Million SEK | -273.207% |
| I-Tech AB | -83.26 Million SEK | 39.923% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 137.133% |
| Cyxone AB (publ) | -16.67 Million SEK | -200.066% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 10.495% |
| Biosergen AB | -1.88 Million SEK | -2556.452% |
| Nanologica AB (publ) | -9.38 Million SEK | -432.818% |
| SynAct Pharma AB | -61.75 Million SEK | 19.005% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -133.579% |
| BioInvent International AB (publ) | -236.3 Million SEK | 78.832% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -278.111% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 25.253% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -865.485% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -140.567% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1583.075% |